netFormulary NHS
North Central London
Joint Formulary
 Search
 Results

Looking for Adalimumab found 24 matches

Formulary items 5 matches
   
Open monograph to display formulary status BNF Category
  Restricted Drug Adalimumab
(Gastroenterology) 		Gastro-intestinal system - Cytokine inhibitors : Treatment of ulcerative colitis and Crohn’s disease - 01.05.03
  Restricted Drug Adalimumab
(Rheumatology) 		Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Restricted Drug Adalimumab
(Uveitis) 		Eye - Immunosuppressants - 11.99.99.99
  Restricted Drug Adalimumab
(Dermatology) 		Skin - Drugs affecting the immune response - 13.05.03
  Restricted Drug Golimumab
(Gastroenterology) 		Gastro-intestinal system - Cytokine inhibitors : Treatment of ulcerative colitis and Crohn’s disease - 01.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA146: Adalimumab for the treatment of adults with psoriasis (13.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab and adalimumab  (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in subsection NICE TA375: Rheumatoid arthritis - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.99.99.99)


 
netFormulary